At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedMar 21, 2023
DataAggregated Company Financials
Companies6
- 7D-8.6%
- 3M-10.3%
- 1Y-21.0%
- YTD-28.0%
Over the last 7 days, the Life Sciences industry has dropped 6.3%, driven by WuXi Biologics (Cayman) declining 7.7%. Overall the industry is down 13% in 12 months. Looking forward, earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 21 Mar 2023 | HK$238.6b | HK$26.4b | HK$2.1b | 22.9x | 115.6x | 9x |
| Thu, 16 Feb 2023 | HK$313.3b | HK$26.5b | HK$2.1b | 25.1x | 149.5x | 11.8x |
| Sat, 14 Jan 2023 | HK$378.5b | HK$26.7b | HK$2.2b | 27.6x | 174.2x | 14.2x |
| Mon, 12 Dec 2022 | HK$288.2b | HK$26.0b | HK$2.0b | 27.9x | 144.4x | 11.1x |
| Wed, 09 Nov 2022 | HK$255.7b | HK$25.6b | HK$1.9b | 24.8x | 137.4x | 10x |
| Fri, 07 Oct 2022 | HK$256.4b | HK$25.7b | HK$1.9b | 20.5x | 134.5x | 10x |
| Sun, 04 Sep 2022 | HK$343.4b | HK$26.3b | HK$2.1b | 27.3x | 167.1x | 13x |
| Tue, 02 Aug 2022 | HK$384.6b | HK$22.3b | HK$2.1b | 12x | 187.6x | 17.2x |
| Thu, 30 Jun 2022 | HK$379.0b | HK$22.4b | HK$2.1b | 15.6x | 182.6x | 16.9x |
| Sat, 28 May 2022 | HK$284.4b | HK$22.3b | HK$2.1b | 13.1x | 138.4x | 12.7x |
| Mon, 25 Apr 2022 | HK$296.8b | HK$22.9b | HK$2.2b | 14.3x | 133.1x | 12.9x |
| Wed, 23 Mar 2022 | HK$314.7b | HK$19.2b | HK$1.5b | 21.1x | 205.9x | 16.4x |
| Fri, 18 Feb 2022 | HK$350.8b | HK$18.7b | HK$2.8b | 24.4x | 124.3x | 18.7x |
| Sun, 16 Jan 2022 | HK$477.6b | HK$18.7b | HK$2.8b | 29.6x | 170.2x | 25.6x |
| Tue, 14 Dec 2021 | HK$528.1b | HK$18.7b | HK$2.8b | 37.1x | 188.6x | 28.3x |
| Thu, 11 Nov 2021 | HK$536.7b | HK$18.6b | HK$2.8b | 35.4x | 192.2x | 28.9x |
| Sat, 09 Oct 2021 | HK$572.2b | HK$18.5b | HK$2.8b | 51.7x | 207.6x | 31x |
| Mon, 06 Sep 2021 | HK$628.0b | HK$18.4b | HK$2.7b | 52.9x | 228.9x | 34.1x |
| Wed, 04 Aug 2021 | HK$679.8b | HK$18.4b | HK$2.7b | 56x | 247.8x | 37x |
| Sat, 08 May 2021 | HK$524.9b | HK$15.7b | HK$1.4b | 47.5x | 363.3x | 33.5x |
| Tue, 09 Feb 2021 | HK$494.9b | HK$13.1b | HK$201.6m | 81.8x | 2455.4x | 37.7x |
| Mon, 02 Nov 2020 | HK$338.5b | HK$11.4b | HK$4.7m | 59.6x | 72765x | 29.8x |
| Thu, 06 Aug 2020 | HK$276.8b | HK$9.7b | -HK$169,775,475.51 | 95.6x | -1630.6x | 28.6x |
| Sun, 10 May 2020 | HK$201.1b | HK$9.2b | HK$329.6m | 91.1x | 610x | 21.7x |
Price to Earnings Ratio
516.2x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 123x which is lower than its 3-year average PE of 6kx.
- The 3-year average PS ratio of 24.0x is higher than the industry's current PS ratio of 9.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 84% per year over the last three years.
- Revenues for these companies have grown 42% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -1.82% | |
| Healthcare | -2.66% | |
| Life Sciences | -8.59% | |
| Clinical Research and Equipment | -8.59% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1521 Frontage Holdings | HK$2.29 | 6.5% +HK$285.1m | -27.3% | PE26.4x |
